Marta Klarić
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marta Klarić has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Dragan Klarić
Department of Hemodialysis, General Hospital Zadar, 23000 Zadar, Croatia
3 shared publications - Danica Galešić Ljubanović
Faculty of Pharmacy and Biochemistry, University of Zagreb, 10000 Zagreb, Croatia
2 shared publications - Petar Šenjug
Department of Pathology, School of Medicine University of Zagreb Zagreb Croatia
2 shared publications - Ivica Horvatić
Department of Nephrology and Dialysis Dubrava University Hospital Zagreb Croatia
1 shared publication - Jagoda Nikić
Nursing School Mlinarska, University of Applied Health Sciences, 10000 Zagreb, Croatia
1 shared publication - Kresimir Galesic
Department of Nephrology and Dialysis, Dubrava University Hospital, 10000 Zagreb, Croatia
1 shared publication
Latest Publications
- Open Access
- 2 November 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (11) , 570
Recurrent Dialyzer-Associated Hypersensitivity with Complement Activation Complicated by Cardiac Arrest: A Case Report
Background: Dialyzer-associated hypersensitivity reactions are rare but potentially life-threatening complications of hemodialysis (HD). Their pathophysiology is heterogeneous. Methods: We report a 49-year-old patient with end-stage chronic kidney disease (CKD G5), severe secondary hyperparathyroidism, poorly controlled arterial hypertension, a long history of heavy smoking, severe coronary and valvular disease, reduced left ventricular ejection fraction, renal anemia, and chronic volume overload. Results: Shortly after initiation of HD with a polysulfone dialyzer (Diacap Pro), she repeatedly developed severe dyspnea, hypoxemia, and marked hypertensive responses. Similar reactions occurred after switching to a cellulose triacetate dialyzer (Sureflux), necessitating temporary conversion to peritoneal dialysis (PD). Progressive PD ultrafiltration failure and loss of residual kidney function eventually required a return to HD. Severe reactions recurred within 15–30 min of treatment despite premedication. During the most severe episode, the patient developed profound hypoxemia (SpO2 55%), severe hypertension (up to 240/130 mmHg), ventricular tachycardia, and cardiac arrest requiring successful cardiopulmonary resuscitation. Immunological evaluation demonstrated normal total IgE (17 U/mL), decreased C3 (0.76 g/L), markedly reduced total hemolytic complement activity (CH50, 18%), and elevated IL-6 (87.5 pg/mL). Chronic HD was successfully reinitiated using an FX CorAL dialyzer with a Helixone® hydro membrane. Since its introduction, no further hypersensitivity reactions have occurred, and corticosteroid, antihistamine, and bronchodilator premedication has been discontinued. This case demonstrates severe recurrent dialyzer-associated hypersensitivity with findings suggestive of complement involvement, complicated by cardiac arrest in a patient with markedly impaired cardiovascular reserve. Conclusions: Successful long-term treatment with a hydrophilic Helixone® dialyzer highlights the importance of individualized dialyzer selection in patients with severe hypersensitivity reactions.
- 2 November 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (11) , 570
Open AccessRecurrent Dialyzer-Associated Hypersensitivity with Complement Activation Complicated by Cardiac Arrest: A Case Report
Background: Dialyzer-associated hypersensitivity reactions are rare but potentially life-threatening complications of hemodialysis (HD). Their pathophysiology is heterogeneous. Methods: We report a 49-year-old patient with end-stage chronic kidney disease (CKD G5), severe secondary hyperparathyroidism, poorly controlled arterial hypertension, a long history of heavy smoking, severe coronary and valvular disease, reduced left ventricular ejection fraction, renal anemia, and chronic volume overload. Results: Shortly after initiation of HD with a polysulfone dialyzer (Diacap Pro), she repeatedly developed severe dyspnea, hypoxemia, and marked hypertensive responses. Similar reactions occurred after switching to a cellulose triacetate dialyzer (Sureflux), necessitating temporary conversion to peritoneal dialysis (PD). Progressive PD ultrafiltration failure and loss of residual kidney function eventually required a return to HD. Severe reactions recurred within 15–30 min of treatment despite premedication. During the most severe episode, the patient developed profound hypoxemia (SpO2 55%), severe hypertension (up to 240/130 mmHg), ventricular tachycardia, and cardiac arrest requiring successful cardiopulmonary resuscitation. Immunological evaluation demonstrated normal total IgE (17 U/mL), decreased C3 (0.76 g/L), markedly reduced total hemolytic complement activity (CH50, 18%), and elevated IL-6 (87.5 pg/mL). Chronic HD was successfully reinitiated using an FX CorAL dialyzer with a Helixone® hydro membrane. Since its introduction, no further hypersensitivity reactions have occurred, and corticosteroid, antihistamine, and bronchodilator premedication has been discontinued. This case demonstrates severe recurrent dialyzer-associated hypersensitivity with findings suggestive of complement involvement, complicated by cardiac arrest in a patient with markedly impaired cardiovascular reserve. Conclusions: Successful long-term treatment with a hydrophilic Helixone® dialyzer highlights the importance of individualized dialyzer selection in patients with severe hypersensitivity reactions.
- Open Access
- 30 July 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (8) , 1212
Crescentic Glomerulonephritis Due to Enterococcal Endocarditis
Glomerulonephritis following an enterococcal endocarditis is an extremely rare and life-threatening condition. We present the case of a 71-year-old patient with rapidly progressive glomerulonephritis following enterococcal endocarditis after surgical replacement of the aortic valve. The combination of antibiotic therapy, corticosteroid therapy and haemodialysis led to an improvement in renal function; however, the severity of cardiac deterioration resulted in a fatal outcome.
- 30 July 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (8) , 1212
Open AccessCrescentic Glomerulonephritis Due to Enterococcal Endocarditis
Glomerulonephritis following an enterococcal endocarditis is an extremely rare and life-threatening condition. We present the case of a 71-year-old patient with rapidly progressive glomerulonephritis following enterococcal endocarditis after surgical replacement of the aortic valve. The combination of antibiotic therapy, corticosteroid therapy and haemodialysis led to an improvement in renal function; however, the severity of cardiac deterioration resulted in a fatal outcome.
- Open Access
- 30 August 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (9) , 1415
Resistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report
Collapsing glomerulopathy (CG) or collapsing focal segmental glomerulosclerosis (cFSGS) is an aggressive disease with a high tendency of progression to end-stage renal disease due to common resistance to conventional immunosuppressants. Rituximab (RTX), a monoclonal antibody against CD20 B cells, showed some benefit in the treatment of CG. We are reporting about female patients with an idiopathic form of CG presenting with nephrotic syndrome (NS) and renal insufficiency resistant to several immunosuppressive agents such as steroids (ST), calcineurin inhibitors (CNI), and cyclophosphamide (CYC). This multidrug-resistant disease responded to RTX with complete remission. Forty-four months after initial RTX administration, a relapse of CG with severe NS and acute renal insufficiency occurred. Repeated application of RTX led to complete remission again. To the best of our knowledge, we are reporting the first case of the relapsing multidrug-resistant form of CG, which responded to RTX. Current data about the treatment of CG with RTX is lacking and is based on rare case reports and small case series. Thus, our report can contribute to determining the role of RTX in the treatment of CG.
- 30 August 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (9) , 1415
Open AccessResistant and Relapsing Collapsing Glomerulopathy Successfully Treated with Rituximab—A Case Report
Collapsing glomerulopathy (CG) or collapsing focal segmental glomerulosclerosis (cFSGS) is an aggressive disease with a high tendency of progression to end-stage renal disease due to common resistance to conventional immunosuppressants. Rituximab (RTX), a monoclonal antibody against CD20 B cells, showed some benefit in the treatment of CG. We are reporting about female patients with an idiopathic form of CG presenting with nephrotic syndrome (NS) and renal insufficiency resistant to several immunosuppressive agents such as steroids (ST), calcineurin inhibitors (CNI), and cyclophosphamide (CYC). This multidrug-resistant disease responded to RTX with complete remission. Forty-four months after initial RTX administration, a relapse of CG with severe NS and acute renal insufficiency occurred. Repeated application of RTX led to complete remission again. To the best of our knowledge, we are reporting the first case of the relapsing multidrug-resistant form of CG, which responded to RTX. Current data about the treatment of CG with RTX is lacking and is based on rare case reports and small case series. Thus, our report can contribute to determining the role of RTX in the treatment of CG.